KR20010022126A - 내인성 유전자 활성화에 의해 사람 단백질을 생성시키는사람 세포계를 확인하는 방법 - Google Patents
내인성 유전자 활성화에 의해 사람 단백질을 생성시키는사람 세포계를 확인하는 방법 Download PDFInfo
- Publication number
- KR20010022126A KR20010022126A KR1020007000696A KR20007000696A KR20010022126A KR 20010022126 A KR20010022126 A KR 20010022126A KR 1020007000696 A KR1020007000696 A KR 1020007000696A KR 20007000696 A KR20007000696 A KR 20007000696A KR 20010022126 A KR20010022126 A KR 20010022126A
- Authority
- KR
- South Korea
- Prior art keywords
- human
- cells
- gene
- proteins
- epo
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 106
- 210000005260 human cell Anatomy 0.000 title claims abstract description 39
- 230000004913 activation Effects 0.000 title claims abstract description 17
- 108090000144 Human Proteins Proteins 0.000 title claims abstract description 15
- 102000003839 Human Proteins Human genes 0.000 title claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 title abstract description 13
- 210000004027 cell Anatomy 0.000 claims abstract description 164
- 238000000034 method Methods 0.000 claims abstract description 29
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 13
- 230000013595 glycosylation Effects 0.000 claims description 12
- 238000006206 glycosylation reaction Methods 0.000 claims description 12
- 239000002609 medium Substances 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 238000011109 contamination Methods 0.000 claims description 8
- 230000004544 DNA amplification Effects 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 6
- 238000004114 suspension culture Methods 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000002458 infectious effect Effects 0.000 claims description 5
- 239000012679 serum free medium Substances 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 3
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 2
- 102000009025 Endorphins Human genes 0.000 claims description 2
- 108010049140 Endorphins Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 2
- 230000023555 blood coagulation Effects 0.000 claims description 2
- 230000008468 bone growth Effects 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 230000002759 chromosomal effect Effects 0.000 claims description 2
- 229960000258 corticotropin Drugs 0.000 claims description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 2
- 230000005966 endogenous activation Effects 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 239000003900 neurotrophic factor Substances 0.000 claims description 2
- 102000021127 protein binding proteins Human genes 0.000 claims description 2
- 108091011138 protein binding proteins Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 102100028471 Eosinophil peroxidase Human genes 0.000 claims 1
- 241000289669 Erinaceus europaeus Species 0.000 claims 1
- 102100027188 Thyroid peroxidase Human genes 0.000 claims 1
- 101710113649 Thyroid peroxidase Proteins 0.000 claims 1
- 229940047120 colony stimulating factors Drugs 0.000 claims 1
- -1 encephalins Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 47
- 102100031939 Erythropoietin Human genes 0.000 description 43
- 239000013612 plasmid Substances 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 12
- 101150002621 EPO gene Proteins 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 230000003321 amplification Effects 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 229960000485 methotrexate Drugs 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 8
- 238000010363 gene targeting Methods 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 108700024394 Exon Proteins 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000001155 isoelectric focusing Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 229940054269 sodium pyruvate Drugs 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100333654 Homo sapiens EPO gene Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001045988 Neogene Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 101150091879 neo gene Proteins 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- OSNSWKAZFASRNG-WNFIKIDCSA-N (2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;hydrate Chemical compound O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O OSNSWKAZFASRNG-WNFIKIDCSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 102100028292 Aladin Human genes 0.000 description 1
- 101710065039 Aladin Proteins 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 241000710118 Maize chlorotic mottle virus Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108700010919 epstein-barr-virus proteins Proteins 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
HepG2 | HT1080 | 나말와 | HeLa | HeLaS3 | |
증식 | |||||
배증 시간 | + | ++ | ++ | +++ | +++ |
현탁 배양 | - | + | + | +/- | + |
가능한 혈청 비함유 | +/- | + | + | + | + |
EPO 생성 | |||||
내인성 | + | - | - | - | - |
일시적/㎖ | 53ng | 65ng | 70ng | 100ng | 480ng |
EPO 글리코실화 (일시적) | - | + | + | + | + |
바이러스 전염성 오염에 대한 시험 | 시험되지 않음 | 없음 | 없음 | 시험되지 않음 | 없음 |
Claims (15)
- 세포 내에 내인적으로 존재하는 표적 유전자를 활성화시킴으로써 사람 단백질을 제조하는데 사용되는 사람 세포계를 선택하는 방법으로서,(a) 사람 세포를 하기 특징의 존재에 대해 시험하고:(i) 원하는 핵산 서열을 갖는 표적 유전자,(ii) 현탁 배양액 중에서의 14일 내의 5배 이상의 개체수의 배증, 및(iii) 혈청 비함유 배지 중에서의 14일 내의 5배 이상의 개체수의 배증;(b) 특징 (i), (ii) 및 (iii)을 만족시키는 세포계를 표적 유전자의 내인성 활성화를 위한 출발 세포계로서 사용하는 방법.
- 제 1항에 있어서, (iv) 배지 중에서 1주일 내에 16 내지 256배의 개체수 배증의 세대 시간을 갖는, 사람 세포계가 사용됨을 특징으로 하는 방법.
- 제 2항에 있어서, 배지 중에서 1주일 내에 64 내지 128배의 개체수 배증을 갖는, 사람 세포계가 사용됨을 특징으로 하는 방법.
- 제 1항 내지 3항 중 어느 한 항에 있어서, (v) 표적 유전자의 내인성 발현을 실질적으로 갖지 않는, 세포계가 사용됨을 특징으로 하는 방법.
- 제 1항 내지 4항 중 어느 한 항에 있어서, (vi) 2개가 넘는 표적 유전자의 염색체 복제물을 함유하는, 세포계가 사용됨을 특징으로 하는 방법.
- 제 1항 내지 5항 중 어느 한 항에 있어서, (vii) 천연 표적 단백질에 필적하는 글리코실화 패턴을 갖는 세포 단백질을 합성하는, 사람 세포계가 사용됨을 특징으로 하는 방법.
- 제 1항 내지 6항 중 어느 한 항에 있어서, (viii) 검출가능한 전염성 오염이 없는, 사람 세포계가 사용됨을 특징으로 하는 방법.
- 사람 세포계 내에서 내인성 유전자 활성화에 의해 사람 단백질을 제조하는 방법으로서, 제 1항에 규정된 특징 (i), (ii) 및 (iii)을 만족시키는 세포계가 사용됨을 특징으로 하는 방법.
- 제 8항에 있어서, 제 2항, 4항, 5항, 6항 및 7항 중 어느 한 항에 규정된 특징 (iv), (v), (vi), (vii) 및 (viii) 중 어느 하나 이상을 추가로 만족시키는 세포계가 사용됨을 특징으로 하는 방법.
- 제 1항 내지 9항 중 어느 한 항에 있어서, EPO, TPO, 콜로니 자극 인자, 혈액 응고에 영향을 미치는 단백질, 인터페론, 인터루킨, 케모킨, 향신경성 인자, 뼈 성장에 영향을 미치는 단백질, 헤지호그 단백질, 종양 성장 인자, 성장 호르몬, ACTH, 엔세팔린, 엔돌핀, 수용체 및 그 밖의 단백질 결합성 단백질로 구성된 군으로부터 선택된 사람 인자를 제조함을 특징으로 하는 방법.
- 제 10항에 있어서, EPO를 제조함을 특징으로 하는 방법.
- 세포 내에 내인적으로 존재하는 표적 유전자를 활성화시킨 후에, 활성 표적 유전자에 의해 코드화되는 폴리펩티드를 수득하는데 사용되는, 제 1항 내지 11항 중 어느 한 항에 따른 방법에 의해 확인된 사람 세포계의 용도.
- 제 12항에 있어서, 폴리펩티드를 대규모 발효기에서 수득하는데 사용됨을 특징으로 하는 용도.
- 사람 세포에서 활성인 이종성 프로모터와 작동적으로 결합되어 있는 내인성 유전자의 복제물을 함유하며, 내인성 유전자에 의해 코드화되는 폴리펩티드를 24시간 당 106개 세포 당 200ng 이상 생성시킬 수 있는 사람 세포계.
- 제 14항에 따른 세포로부터 유전자 증폭에 의해 수득될 수 있는 사람 세포계로서, 사람 세포에서 활성인 이종성 프로모터와 각각 작동적으로 결합되어 있는 내인성 유전자의 다수의 복제물을 함유하며, 내인성 유전자에 의해 코드화되는 폴리펩티드를 24시간 당 106개 세포 당 1000ng 이상 생성시킬 수 있는 사람 세포계.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97112640 | 1997-07-23 | ||
EP97112640.4 | 1997-07-23 | ||
EP97121073.7 | 1997-12-01 | ||
EP97121073 | 1997-12-01 | ||
US09/113,692 | 1998-07-10 | ||
US9/113,692 | 1998-07-10 | ||
US09/113,692 US6548296B1 (en) | 1997-07-23 | 1998-07-10 | Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof |
PCT/EP1998/004584 WO1999005267A1 (de) | 1997-07-23 | 1998-07-22 | Identifizierung humaner zellinien zur produktion humaner proteine durch endogene genaktivierung |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010022126A true KR20010022126A (ko) | 2001-03-15 |
KR100622203B1 KR100622203B1 (ko) | 2006-09-07 |
Family
ID=40933395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020007000696A KR100622203B1 (ko) | 1997-07-23 | 1998-07-22 | 내인성 유전자 활성화에 의해 사람 단백질을 생성시키는 사람 세포주를 확인하는 방법 |
Country Status (6)
Country | Link |
---|---|
US (2) | US6846673B2 (ko) |
JP (2) | JP5896960B2 (ko) |
KR (1) | KR100622203B1 (ko) |
AR (1) | AR016774A1 (ko) |
CO (1) | CO4790179A1 (ko) |
PT (1) | PT1000154E (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100622203B1 (ko) * | 1997-07-23 | 2006-09-07 | 로셰 디아그노스틱스 게엠베하 | 내인성 유전자 활성화에 의해 사람 단백질을 생성시키는 사람 세포주를 확인하는 방법 |
US20050019914A1 (en) * | 2003-07-24 | 2005-01-27 | Aventis Pharma Deutschland Gmbh | Perfusion process for producing erythropoietin |
EA009326B1 (ru) * | 2007-04-06 | 2007-12-28 | Петр Генриевич ЛОХОВ | Способ определения качества клеточной культуры |
WO2012050175A1 (ja) | 2010-10-15 | 2012-04-19 | 日本ケミカルリサーチ株式会社 | 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法 |
JP6652334B2 (ja) | 2014-05-31 | 2020-02-19 | Jcrファーマ株式会社 | ウリジンとn−アセチル−d−マンノサミンとを含有する培地 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin |
JPS62171696A (ja) | 1986-01-23 | 1987-07-28 | Sumitomo Chem Co Ltd | ヒトエリスロポエチンの製造方法 |
US4954437A (en) | 1986-09-15 | 1990-09-04 | Integrated Genetics, Inc. | Cell encoding recombinant human erythropoietin |
ES2127458T3 (es) | 1989-11-06 | 1999-04-16 | Cell Genesys Inc | Produccion de proteinas utilizando recombinacion homologa. |
US5328844A (en) | 1990-05-09 | 1994-07-12 | University Of Colorado Foundation, Inc. | Culture media for mammalian cells |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
NZ245015A (en) | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
CA2298412C (en) * | 1997-07-23 | 2010-10-19 | Roche Diagnostics Gmbh | Identification of human cell lines for the production of human proteins by endogenous gene activation |
KR100622203B1 (ko) * | 1997-07-23 | 2006-09-07 | 로셰 디아그노스틱스 게엠베하 | 내인성 유전자 활성화에 의해 사람 단백질을 생성시키는 사람 세포주를 확인하는 방법 |
KR100641969B1 (ko) * | 1997-07-23 | 2006-11-06 | 로셰 디아그노스틱스 게엠베하 | 내인성 유전자 활성화에 의한 에리트로포이에틴의제조방법 |
US6548296B1 (en) * | 1997-07-23 | 2003-04-15 | Roche Diagnostics Gmbh | Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof |
-
1998
- 1998-07-22 KR KR1020007000696A patent/KR100622203B1/ko not_active IP Right Cessation
- 1998-07-22 PT PT98942592T patent/PT1000154E/pt unknown
- 1998-07-23 CO CO98042018A patent/CO4790179A1/es unknown
- 1998-07-23 AR ARP980103618A patent/AR016774A1/es active IP Right Grant
-
2002
- 2002-04-02 US US10/112,755 patent/US6846673B2/en not_active Expired - Lifetime
-
2004
- 2004-11-08 US US10/982,880 patent/US7214514B2/en not_active Expired - Fee Related
-
2013
- 2013-07-04 JP JP2013140485A patent/JP5896960B2/ja not_active Expired - Lifetime
-
2014
- 2014-07-02 JP JP2014136448A patent/JP6047524B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2013240335A (ja) | 2013-12-05 |
CO4790179A1 (es) | 1999-05-31 |
AR016774A1 (es) | 2001-08-01 |
US20020164792A1 (en) | 2002-11-07 |
PT1000154E (pt) | 2007-03-30 |
US7214514B2 (en) | 2007-05-08 |
US6846673B2 (en) | 2005-01-25 |
JP2014193187A (ja) | 2014-10-09 |
JP5896960B2 (ja) | 2016-03-30 |
US20050090007A1 (en) | 2005-04-28 |
JP6047524B2 (ja) | 2016-12-21 |
KR100622203B1 (ko) | 2006-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7186529B2 (en) | Preparation of erythropoietin by endogenous gene activation | |
ES2273434T3 (es) | Obtencion de la eritropoyetina mediante activacion genica endogena. | |
JP6047524B2 (ja) | 内因性遺伝子の活性化によるヒト蛋白質の生産のためのヒト細胞株の同定 | |
US6395484B1 (en) | Identification of human cell lines for the production of human proteins by endogenous gene activation | |
JPH05503015A (ja) | 哺乳類発現ベクター | |
US6555373B1 (en) | Methods for identifying human cell lines useful for endogenous gene activation isolated human cell lines identified thereby, and uses thereof | |
US4939088A (en) | Sustained production of recombinant gamma interferon using an Epstein-Barr virus replicon | |
KR100274225B1 (ko) | 조류 세포를 이용한 이종 단백질 생산 시스템 | |
MXPA00000677A (en) | Identification of human cell lines for the production of human proteins by endogenous gene activation | |
AU776280B2 (en) | Production of erythropoietin by endogenous gene activation | |
Hudson | Development of vectors allowing efficient heterologous-gene expression in stable myeloma-cell transfectants | |
MXPA00000745A (en) | Production of erythropoietin by endogenous gene activation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120827 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20130822 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140821 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150820 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160818 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170825 Year of fee payment: 12 |
|
EXPY | Expiration of term |